Fundraising Fox
Longeveron
NASDAQ: LGVNMiami, US · Founded 2014 · Delaware corporation · 41 employees on LinkedIn · 2 known investors
Find your way into Longeveron
656 people in our graph share verified history with the Longeveron team — schools, employers, funds. One of them is your warm intro.
Kevin M. Slawinunlockedknows Devin Blass · together at Bellicum Pharmaceuticals, Inc. (overlapped)
knows the team · via Longeveron
×2knows the team · via Otsuka Pharmaceutical Companies (U.S.)
×2knows the team · via Seres Therapeutics
×6knows the team · via MD Anderson Cancer Center
Longeveron is a clinical-stage biotechnology company developing allogeneic cellular therapies for life-threatening conditions affecting children and the elderly. Its investigational candidate is being evaluated for indications including Hypoplastic Left Heart Syndrome, Pediatric Dilated Cardiomyopathy, Alzheimer's Disease, and age-related frailty.
Founders & leadership
Longeveron was founded in 2014 by Joshua M. Hare.
JM
Joshua M. HareCo-FounderJoshua Hare is a cardiologist and stem cell researcher with over 18 years at the University of Miami Miller School of Medicine, where he held the Louis Lemberg Professorship and founded the Interdisciplinary Stem Cell Institute; he is founder and Chair of Longeveron, a publicly listed biotechnology company developing cellular therapies for pediatric and age-related disorders.
WH
Wa'el HashadChief Executive Officer and Member of the Board2023–2025Wa'el Hashad is an executive with over 25 years of experience in general management, sales, and marketing, including brand development and launch across US and international markets. He has worked across multiple therapeutic areas including neuroscience, cardiovascular, oncology, and others, and has led business development efforts including partnerships, licensing, and acquisitions.
NA
Nataliya AgafonovaChief Medical Officer/ Global Development LeadNataliya Agafonova is a physician-scientist with over 20 years of clinical development experience in pharmaceutical and biotechnology organizations, working across autoimmune disease, neuroscience, rare disease, and regenerative medicine. She leads development efforts at Longeveron, a clinical-stage biotech company developing cellular therapies for conditions including heart disease and neurodegenerative disorders.
JC
James ClavijoChief Financial Officer2019–2023James Clavijo is Executive Officer of Longeveron, a clinical-stage biotechnology company developing allogeneic cellular therapies for life-threatening conditions in children and the elderly. He has over 20 years of experience in finance and corporate strategy, including raising over $1 billion in capital, leading IPOs and M&A transactions, and advising companies through restructurings and capital markets activities.
SH
Stephen H. WillardChief Executive Officer
DB
Devin BlassChief Technology OfficerDevin Blass is Chief Technology Officer and Senior Vice President of Chemistry, Manufacturing, and Controls at Longeveron, overseeing manufacturing operations and regulatory strategy for cell-based therapies. With nearly two decades in cell therapy development, he previously held senior operations roles at the New York Blood Center, Talaris Therapeutics, Bellicum Pharmaceuticals, Mesoblast, and MD Anderson Cancer Center.
GG
Geoff GreenNamed on SEC filing
Board
RS
Rock SofferBoard director
DS
Donald SofferManager of the Company.
RJ
Roger Joseph HajjarBoard director
Investors · 2
Reported raises · per SEC filings
Form D private placements$37.4M disclosed across 4 of 9 rounds · 2017–2026
▶$15.9MraisedMar 2026 · 7 investors · BiotechnologyRule 506(b)
▶$15.9MraisedMar 2026 · 7 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Paul LehrExecutive Officer
- Nataliya AgafonovaExecutive Officer
- Rock SofferDirector
- George Paletta, Jr.Director
- Ursula UngaroDirector
- Stephen H. WillardExecutive Officer
- Devin BlassExecutive Officer
- Lisa A. LocklearExecutive Officer
- Roger Joseph HajjarDirector
- Joshua M. HareExecutive Officer, Director
- Offering amount
- $33.5M
- Amount sold
- $15.9M
- Sales commissions
- $2.2M
- Placement agents
- Michael Vasinkevich, Craig Schwabe, Noam Rubinstein, Charles Worthman
- First sale
- Mar 2026
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$9.5MofferedJul 2024 · 3 investors · BiotechnologyRule 506(b)
▶$9.5MofferedJul 2024 · 3 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Roger Joseph HajjarDirector
- Joshua M. HareExecutive Officer, Director
- Neil E. HareDirector
- Paul LehrExecutive Officer
- Neha J. MotwaniDirector
- Lisa A. LocklearExecutive Officer
- Richard KenderDirector
- Ursula UngaroDirector
- Wa'el HashadExecutive Officer, Director
- Nataliya AgafonovaExecutive Officer
- Rock SofferDirector
- Khoso BaluchDirector
- Offering amount
- $9.5M
- Sales commissions
- $630K
- Placement agents
- Craig Schwabe, Charles Worthman, Michael Vasinkevich, Noam Rubinstein
- First sale
- Jul 2024
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$9.4MofferedJun 2024 · 3 investors · BiotechnologyRule 506(b)
▶$9.4MofferedJun 2024 · 3 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Khoso BaluchDirector
- Paul LehrExecutive Officer
- Lisa A. LocklearExecutive Officer
- Rock SofferDirector
- Richard KenderDirector
- Neil E. HareDirector
- Wa'el HashadExecutive Officer, Director
- Joshua M. HareExecutive Officer, Director
- Nataliya AgafonovaExecutive Officer
- Douglas LosordoDirector
- Ursula UngaroDirector
- Offering amount
- $9.4M
- Sales commissions
- $424.5K
- Placement agents
- Michael Vasinkevich, Charles Worthman, Craig Schwabe, Noam Rubinstein
- First sale
- Jun 2024
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$12.4MofferedApr 2024 · 3 investors · BiotechnologyRule 506(b)
▶$12.4MofferedApr 2024 · 3 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Cathy RossDirector
- Ursula UngaroDirector
- Khoso BaluchDirector
- Jeffrey PfefferDirector
- Wa'el HashadExecutive Officer, Director
- Neil E. HareDirector
- Paul LehrExecutive Officer
- Nataliya AgafonovaExecutive Officer
- Lisa LocklearExecutive Officer
- Douglas LosordoDirector
- Rock SofferDirector
- Joshua M. HareExecutive Officer, Director
- Offering amount
- $12.4M
- Sales commissions
- $436.8K
- Placement agents
- Charles Worthman, Noam Rubinstein, Craig Schwabe, Michael Vasinkevich
- First sale
- Apr 2024
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$2.6MofferedJan 2024 · 1 investors · BiotechnologyRule 506(b)
▶$2.6MofferedJan 2024 · 1 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Douglas LosordoDirector
- Lisa LocklearExecutive Officer
- Jeffrey PfefferDirector
- Joshua M. HareExecutive Officer, Director
- Nataliya AgafonovaExecutive Officer
- Neil E. HareDirector
- Wa'el HashadExecutive Officer, Director
- Khoso BaluchDirector
- Cathy RossDirector
- Rock SofferDirector
- Ursula UngaroDirector
- Paul LehrExecutive Officer
- Offering amount
- $2.6M
- Sales commissions
- $165.6K
- Placement agents
- Noam Rubinstein, Michael Vasinkevich, Craig Schwabe, Charles Worthman
- First sale
- Dec 2023
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$8.4MofferedOct 2023 · 1 investors · BiotechnologyRule 506(b)
▶$8.4MofferedOct 2023 · 1 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Cathy RossDirector
- Rock SofferDirector
- Douglas LosordoDirector
- Lisa A. LocklearExecutive Officer
- Paul LehrExecutive Officer
- Wa'El HashadExecutive Officer, Director
- Joshua M. HareExecutive Officer, Director
- Ursula UngaroDirector
- Jeffrey PfefferDirector
- Khoso BaluchDirector
- Neil E. HareDirector
- Nataliya AgafonovaExecutive Officer
- Offering amount
- $8.4M
- Sales commissions
- $280K
- Placement agents
- Noam Rubinstein, Michael Vasinkevich, Craig Schwabe, Charles Worthman
- First sale
- Oct 2023
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$20.5MraisedDec 2021 · 20 investors · BiotechnologyRule 506(b)
▶$20.5MraisedDec 2021 · 20 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Geoff GreenExecutive Officer
- Paul LehrExecutive Officer
- Ursula UngaroDirector
- Donald SofferDirector
- Rock SofferDirector
- Douglas LosordoDirector
- Neil HareDirector
- Erin BorgerDirector
- Cathy RossDirector
- Joshua HareExecutive Officer, Director
- James ClavijoExecutive Officer
- Offering amount
- $20.5M
- Amount sold
- $20.5M
- Sales commissions
- $1.6M
- Placement agents
- EF Hutton, division of Benchmark Investments, LLC
- First sale
- Dec 2021
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$955KraisedFeb 2020 · 5 investors · BiotechnologyRule 506(b)
▶$955KraisedFeb 2020 · 5 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Donald SofferDirector
- James ClavijoExecutive Officer
- Neil E. HareDirector
- Geoff GreenExecutive Officer
- Joshua M. HareExecutive Officer, Director, Promoter
- Paul LehrExecutive Officer
- Offering amount
- $25M
- Amount sold
- $955K
- Minimum investment
- $50K
- First sale
- Oct 2017
- Incorporated
- Limited Liability Company, Delaware
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Valuation · disclosed
Disclosed events$187.1Mvaluation at IPOFeb 2021 · $10.00/share · 424B4
filing ↗Source: SEC prospectus filings, and round valuations the company or its investors disclosed — follow each entry's link for the claim.
Competitors · 4
by search overlap
Regeneron NASDAQ: REGN www.regeneron.com51 shared keywordsRegeneron is a biotechnology company that develops medicines ranging from biologics to genetic medicines to treat serious diseases across areas such as metabolic disease, ophthalmology, and rare disease. The company focuses on research and development driven by human biology, with a clinical trial pipeline addressing conditions like generalized myasthenia gravis.
Bioworld29 shared keywordsBioWorld is a suite of daily news and data services covering therapeutics, medical technology, biopharma business transactions, and drug R&D, serving biopharmaceutical and medtech industry professionals. Owned by Clarivate, it publishes products including BioWorld, BioWorld Science, and BioWorld Asia with reporting from writers stationed globally.
Eledon26 shared keywordsEledon Pharmaceuticals is a clinical-stage biotechnology company developing immunology-based therapies, with a focus on protecting transplanted organs from rejection and treating autoimmune and neurodegenerative diseases including ALS. The company's lead candidate is tegoprubart, an anti-CD40L antibody.
Geron24 shared keywordsGeron is a biopharmaceutical company focused on developing therapies for blood cancer. The company has over 30 years of experience in research and clinical development.
Companies competing with Longeveron for the same Google search keywords, organic and paid, via search-intersection analysis.
Frequently asked questions
- What does Longeveron do?
- Longeveron is a clinical-stage biotechnology company developing allogeneic cellular therapies for life-threatening conditions affecting children and the elderly. Its investigational candidate is being evaluated for indications including Hypoplastic Left Heart Syndrome, Pediatric Dilated Cardiomyopathy, Alzheimer's Disease, and age-related frailty.
- Who founded Longeveron?
- Longeveron was founded by Joshua M. Hare in 2014.
- Who are Longeveron's investors?
- Longeveron's investors include Maryland TEDCO, TEDCO.
- How much funding has Longeveron raised?
- Longeveron has disclosed $37.4M raised across 4 of its 9 known rounds.
- Where is Longeveron headquartered?
- Longeveron is headquartered in Miami, US.